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Abstract 
 
 
Three separate influenza pandemics have emerged in the human population since 
1918, each characterized by viruses that lack N-linked glycosylation sites on the globular 
head of the hemagglutinin protein.  In contrast, recent non-pandemic isolates have 
acquired such sites.  Here we constructed isogenic viruses containing differing numbers 
of additional N-linked glycosylation sites to assess the impact on the host immune 
response.  These studies show that mice infected with a glycosylated virus remain 
susceptible to challenge with a non-glycosylated virus, glycosylated viruses elicit an 
inferior immune response, and in this context T-cell pathology and death may occur.  We 
conclude from these data that glycosylation leads to a lack of neutralization coupled with 
a robust T-cell response.  Specifically, glycosylation of HA seems to shield neutralizing 
antibody epitopes while leaving T-cell epitopes unaffected.  These results may be 
particularly significant in the context of the recent influenza pandemic. 
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Chapter 1:  Introduction 
 
 
Influenza viruses are part of the Orthomyxoviridae family, which consists of 
influenza A, B, and C viruses, Isavirus, and Thogotovirus.  This family consists of 
viruses that have a negative-sense, single-stranded, and segmented RNA genome.  
Influenza A viruses are classified by hemagglutinin (HA) and neuraminidase (NA) 
subtype.  Currently there are 16 different HA subtypes (H1 to H16) and 9 different NA 
subtypes (N1 to N9).  The influenza A virus genome consists of 8 segments that encode 
for 11 proteins.  The two proteins used for viral subtyping, the HA and NA surface 
glycoproteins, are found anchored in the envelope of the virus.  The HA protein is 
responsible for receptor binding and fusion of the virus.  The HA protein is important 
also as the major antigenic protein of influenza A viruses.  The NA protein is responsible 
for viral cleavage from host receptors allowing for viral release.  The HA, NA, and 
matrix protein 2 (M2) are the external proteins of influenza A viruses.  The internal 
proteins consist of matrix protein 1 (M1), polymerase basic 1 and 2 (PB1 and PB2), 
polymerase acid (PA), nucleoprotein (NP), non-structural proteins 1 and 2 (NS1 and 
NS2), and PB1-F2 an alternate reading frame protein from PB1 [1]. 
 
Upon initial infection, influenza viruses gain entry to the host cell through the HA 
protein binding to sialic acid residues present on cell surface glycoproteins.  Different 
influenza viruses can have different specificities for different sialic acid linkages.  
Viruses then enter the cell by receptor-mediated endocytosis, the virus is then uncoated to 
allow for fusion of the HA membrane with the cellular membrane based on a low pH-
induced conformational change of the HA molecule [1;2]. Viral RNPs then make their 
way into the nucleus to replicate using cellular machinery.  The newly produced RNPs 
are then transported to the cytoplasm for assembly [3].  After packaging of the complete 
genome, the newly formed viral membrane again fuses with the cellular membrane 
initiating budding and release [1].  The NA protein can then cleave the viral particle from 
the cell membrane allowing for viral release. 
 
One important aspect of influenza is the ability of the virus to rapidly mutate to 
create antigenically distinct strains [4].  This can occur through two distinct mechanisms, 
drift and shift.  Drift is the natural accumulation of mutations due to the lack of a proof-
reading mechanism found in RNA polymerase.  In the case of influenza HA, many of the 
mutations occur in antigenic regions, leading to mostly similar strains of virus that are 
none-the-less antigenically distinct.  On the other hand, shift occurs due to the 
reaasortment of genes from different viruses, usually swapping a surface antigen from 
one virus to another, creating a novel virus.  Antigenic shift is thought to be the cause of 
the majority of influenza pandemics.  
 
One common alteration is the acquisition of additional n-linked glycosylation 
sites in and around the HA globular head.  Glycosylation is a common post-translational 
modification made to many proteins.  There are two types of glycosylation, n-linked and 
o-linked.  Both the HA and NA proteins carry sites for potential n-linked glycosylation, 
where oligosaccharide chains are attached to the asparagine residues of the consensus n-
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linked glycosylation sequence, Asn-X-Ser/Thr, where X can be any amino acid but 
proline.  As the HA protein mutates frequently, there is much potential for it to acquire 
this consensus sequence [5;6]. 
  
Since 1918, there have been three human influenza A pandemics (1918 H1N1 
Spanish, 1957 H2N2 Asian and 1968 H3N2 Hong Kong).  Combined, these pandemics 
have caused million of deaths worldwide.  In each case, the acquisition of a novel 
hemagglutinin (HA) glycoprotein was the prevailing factor that led to pandemic status, as 
the HA protein is the primary target of neutralization by the immune system.  As each of 
these pandemics, from different subtypes, has been introduced to the human population 
they have shared one common trait, the lack of glycosylation sites on the globular head of 
the HA protein.  In the case of each of these subtypes, as the viruses evolved in the 
human population they started to acquire these sites.  Table 1 shows the acquisition of 
these sites for the H3N2 subtype.  In 1968 when this subtype entered the human 
population it possessed 6 potential glycosylation sites, eventually acquiring 11 sites by 
2002.  This pattern is also seen in the H1N1 and H2N2 subtypes.  Alternatively, influenza 
B viruses also have the ability to acquire these sites, but do not show this same pattern of 
progressive additions (Table 2). 
 
The significance of glycosylation on the globular head of influenza HA is poorly 
understood.  Studies have shown that while glycosylation can affect receptor binding 
activity, cell fusion and intracellular transport are not affected (2).  Studies have also 
shown that addition of a glycosylation site can allow viral escape from a monoclonal 
antibody [7].  Thus glycosylation can change viral antigenicity without deficits in 
biological activity [7;8].  As previous studies in our lab have shown, increased 
glycosylation of an H3N2 virus leads to decreased virulence, at least partially the result 
of more efficient clearance of the virus by surfactant protein D (SP-D), an important part 
of the innate defense against influenza [9].  SP-D activity was shown to be dependent on 
specific glycosylation sites; increased clearance by SP-D was also shown to be relevant 
in other influenza subtypes [10].  On the other hand, the loss of a glycosylation site leads 
to increased virulence and resistance to murine collectins [11].   Thus the addition of 
glycosylation to the HA leads to improved clearance by the innate immune system and 
decreased virulence.  This led us to question if there was a tradeoff between enhanced 
evasion of adaptive immune responses at the expense of enhanced clearance by innate 
immune responses, specifically by SP-D. 
 
 It has been postulated previously that the function of glycosylation on the globular 
head of the HA protein is to shield antigenic sites.  We therefore questioned what the 
effect of infection with highly glycosylated virus would have on the adaptive immune 
system when compared to infection with a less glycosylated virus.  To investigate the 
consequence on the adaptive immune response of successive exposures to glycosylated 
and then non-glycosylated viruses, we designed a murine model system.  HK68 2:6 
mutants (viruses containing HA and Neuraminidase (NA) genes from HK68 and internal 
genes from mouse adapted PR8) created previously [9] were used to sequentially infect 
mice.  This allowed us to access the impact of glycosylation status on disease 
progression, antibody response, and T-cell response.   
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Table 1.  Evolutionary acquisition of glycosylation in H3N2 viruses 
 
Virus Potential Glycosylation  
Sites 
Number of 
Potential Sites 
A/Hong Kong/1/68 8, 22, 38, 81, 165, 285 6 
A/Port Chalmers/1/73 8, 22, 38, 63, 81, 165, 285 7 
A/Victoria/3/75 8, (9), 22, 38, 63, 126, 165, 285 7 (8) 
A/Texas/1/77 8, 22, 38, 63, 126, 165, 285 7 
A/Leningrad/360/86 8, 22, 38, 63, 126, 165, 246, 285 8 
A/Memphis/6/86 8, 22, 38, 63, 126, 165, 246, 285 8 
A/Memphis/8/88 8, 22, 38, 63, 126, 165, 246, 285 8 
A/Beijing/385/89 8, 22, 38, 63, 126, 165, 246, 285 8 
A/Memphis/7/90 8, 22, 38, 63, 126, 165, 246, 285 8 
A/Beijing/32/92 8, 22, 38, 63, 126, 165, 246, 285 8 
A/Wuhan/359/95 8, 22, 38, 63, 126, 165, 246, 285 8 
A/Sydney/5/97 8, 22, 38, 63, 122, 126, 133, 165, 246, 
285 
10 
A/Panama/2007/99 8, 22, 38, 63, 122, 126, 133, 144, 165, 
246, 285 
11 
A/Fujian/411/02 8, 22, 38, 63, 122, 126, 133, 144, 165, 
246, 285 
11 
 
NOTE:  Numbers in bold represent conserved glycosylation sites found in the stalk of the 
influenza hemagglutinin protein.  Non-bold numbers represent glycosylation sites 
acquired during the evolution of the virus.  
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Table 2.  Acquisition of glycosylastion sites in influenza B viruses 
 
Virus Lineage 145 195-197 231-233 Total Potential 
Sites 
B/Hong Kong/73 I Yes No No 7 
B/Hong Kong/8/73 I Yes No No 7 
B/Singapore/222/79 II Yes No Yes 7 
B/Victoria/2/87 III Yes No No 6 
B/Yamagata/16/88 II Yes No Yes 7 
B/Memphis/3/89 III Yes No No 6 
B/Panama/45/90 II Yes Yes Yes 8 
B/Houston/1/91 II Yes Yes Yes 8 
B/Sichuan/8/92 II Yes No No 6 
B/Beijing 184/93 II Yes No No 6 
B/Memphis/5/93 II Yes Yes Yes 8 
B/Nanchang/630/94 III Yes No No 6 
B/Houston/2/96 II Yes Yes No 7 
B/Memphis/12/97 II Yes Yes No 7 
B/Nanchang/2/97 III Yes No Yes 7 
B/Yamanashi/166/98 II Yes Yes No 7 
B/Maryland/1/01 II Yes Yes No 7 
B/Nebraska/2/01 II Yes Yes No 7 
B/Los Angeles/1/02 III Yes Yes Yes 8 
B/Memphis/13/03 III Yes Yes Yes 8 
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The results of these experiments demonstrated the following: (i) animals exposed 
to a glycosylated virus remain susceptible to infection and mortality by a non-
glycosylated influenza virus, (ii) a heavily glycosylated virus may induce an inferior and 
non-neutralizing antibody response, and (iii) in a scenario of low antibody cross-
reactivity, T-cell pathology can ensue. In conclusion, we suggest that exposure to a 
glycosylated virus prior to exposure to a non-glycosylated virus can render a host 
deficient in protective antibodies, particularly neutralizing antibodies, and susceptible to 
T-cell-driven pathology and death.     
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Chapter 2:  Materials and Methods 
 
 
Mice 
 
Six- to eight-week-old female Balb/c mice (Jackson Laboratory, Bar Harbor, ME) 
were maintained in a Biosafety Level 2 facility in the Animal Resource Center at St. Jude 
Children’s Research Hospital (Memphis, TN).  Mice were allowed to acclimate for 5-7 
days before beginning experiments.  All experiments were approved by the Animal Care 
and Use Committee at SJCRH and were done under general anesthesia with inhaled 
isoflurane 2.5% unless otherwise noted. 
 
 
Viral Infections 
 
Mice were initially infected on day 0 with the appropriate virus.  Mice were 
inoculated i.n. with 1 X 104 TCID50 in 100µl volume.  Three weeks later (day 21), or 121 
days in the case of delayed challenge, mice were inoculated i.n. with 1 X 106 TCID50 in 
100µl volume.  Mice were monitored for morbidity (weight loss) and mortality 
(survival).  Mice that lost more than 30% of their initial body weight were euthanized and 
recorded as dying that day. 
 
 
Lung Titers 
 
Mice were euthanized by CO2 asphyxiation.  Lungs were aseptically harvested, 
washed twice in PBS, and placed in 500µl of sterile PBS.  Lungs were then homogenized 
using an Omni Tissue Homogenizer (Omni International, Marietta, GA).  Homogenates 
were pelleted for 5 minutes at 10,000 rpm.  The supernatants were then serial diluted 10-
fold in MDCK infection media.  MDCK monolayers were inoculated with 100µl of each 
dilution.  Infection of individual wells was tested using a standard hemagglutination 
assay. 
 
 
Histological Examination 
 
Lungs were removed immediately following euthanasia, inflated, and fixed in 
10% neutral buffered formalin overnight.  The lungs were processed routinely, embedded 
in paraffin, sectioned at 5µm, stained with hematoxylin and eosin or CD3, and examined 
microscopically for histopathologic alterations.    
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Serum Collection and Treatment 
 
Clotted blood collected from the retro-orbital plexus of anesthetized mice 20 or 
120 days after initial infection were centrifuged for 10min at 6000 x g.  100µl serum was 
treated with 300µl receptor-destroying enzyme (RDE) (Denka Seiken CO. LTD., United 
Kingdom).  300µl of 2.5% sodium citrate and PBS were added and sera were used in 
immune assays. 
 
 
Immune Assays 
 
RDE-treated sera were analyzed for influenza-reactive antibody using standard HI 
titer, microneutralization, and ELISA assays.  For HI assays sera and appropriate virus 
were incubated together for one hour.  Chicken red blood cells were used to test for 
agglutination.  Titers are reported as the reciprocal of the final serum dilution that did not 
inhibit hemagglutination.  
 
For microneutralization assays, MDCK cells were inoculated with serum: virus 
mixtures and an antibody specific for influenza A virus nucleoprotein (antibody info) was 
used to detect infection of MDCK cells by the virus.  Microneutralization titers are 
reported as the reciprocal of the final serum dilution that neutralizes virus to a level 
below one-half of the OD490 seen in virus control wells.   
 
For ELISA, 96 well plates (Becton Dickinson and Company, Franklin Lakes, NJ, 
USA) were coated with appropriate concentrated virus and incubated overnight at 4°C.  
Plates were washed and then blocked for 2 hours at RT.  RDE-treated sera was serially 
diluted in blocking buffer through the plate and incubated overnight at 4°C.  Plates were 
washed and incubated with IgG, IgG1, or IgG2a antibodies (Southern Biotech, 
Birmingham, AL, USA) diluted in blocking buffer for 2 hours.  Plates were washed and 
substrate buffer (p-nitrophenyl phosphate, Sigma) was added for 1 hour.  Plates were read 
at 405 nm using Multiskan Ascent® plate reader (Labsystems, Helsinki, Finland).  
Reciprocal serum antibody titers were calculated at 50% maximal binding. 
 
 
Broncho-Alveolar Lavage for Cell Counts 
 
Following euthanasia by CO2 inhalation, the trachea was exposed, nicked, and a 
catheter (Becton Dickinson and Company, Franklin Lakes, NJ, USA) was inserted into 
the nick.  Lungs were lavaged twice with 1.5ml cold PBS+HBBS (Hanks’ Balanced Salt 
Solution) (Mediatech Inc, Manassas, VA, USA).  The total number of viable cells per ml 
was counted on a coulter counter using 100µl aliquot.  Cells were then stained with T-cell 
antibodies and analyzed by flow cytometry. 
 
. 
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Depletion of CD4+ and CD8+ T Cells 
 
Mice were depleted of CD4 (GK 1.5 mAb) or CD8 (2.43.1 mAb), or both, by 
intraperitoneal inoculation with 100µl of appropriate antibody or both antibodies.  
Depletion began 3 days prior to infection and inoculations were given every other day 
until 5 days after infection.  Blood was collected from depleted mice to test for depletion 
as analyzed by FACS.   
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Chapter 3:  Infection of Mice with a Highly Glycosylated Influenza Virus Followed 
by Challenge with a Virus Exhibiting Less Glycosylation Can Lead to Death 
 
 
To test the concept that glycosylation status is affecting the adaptive immune 
response towards influenza HA, we first looked to see if re-infection with a low 
glycosylated virus was possible after initial infection with a highly glycosylated virus.  
Since the two viruses are antigenically identical except for glycosylation status, re-
infection should only be possible if glycosylation status is reducing the generation of 
adaptive immune responses.  We therefore utilized three isogenic virus stocks with 0 
(WT), 2 (+2) and 4 (+4) n-linked glycosylation sites on the globular head. Mice were 
infected on day 0 with +2 or +4 viruses (1 X 104 TCID50) and then challenged on day 21 
with WT (1 X 106 TCID50).  Figure 1 shows that mice initially infected with +4 lost a 
significant amount of weight upon WT challenge.  However, mice initially infected with 
+2 lost no weight upon WT challenge.  Mice initially infected with WT also showed no 
weight loss upon WT challenge (data not shown).  Figure 2 shows the survival of these 
same mice.  Over 80% of +4 infected mice succumbed to WT challenge, whereas none of 
the +2 infected mice succumbed to WT challenge.  We therefore discovered that mice 
infected with +4 were not protected from WT challenge, demonstrating that exposure to a 
highly glycosylated virus can yield inferior protection against subsequent challenge with 
a non-glycosylated virus.   
 
We then questioned whether the viral load was responsible for the weight loss 
seen in mice initially infected with +4.  To do this we looked at viral lung titers of mice 
previously exposed to PBS, WT, +2, or +4 on days 1, 3, and 5 post-WT challenge.  As 
shown in Figure 3, we found that +4 infected mice had detectable virus in their lungs 
only on day 1 after WT challenge, but that the virus had already started to be cleared on 
day 1 and was completely cleared by day 3.  We therefore discovered that the morbidity 
and mortality seen in +4 infected mice upon WT challenge could not be entirely 
explained by a higher viral load. 
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Figure 1.  Mice infected with a highly glycosylated virus and re-infected with a virus 
exhibiting less glycosylation suffer weight loss.  Mice were infected on day 0 with virus 
(see legend) and then challenged on day 21 with WT virus.  Groups of 6 mice were 
infected with +2 or +4 virus.  Surviving animals were weighted thereafter.  ANOVA 
analyses demonstrated a significant difference (P<0.05) between mice infected with +4 
and +2 viruses on days 2-5. 
 
11 
 
 
 
Figure 2.  Mice infected with a highly glycosylated virus and re-infected with a virus 
exhibiting less glycosylation succumb. Mice were infected on day 0 with initial 
infection (see legend) virus then challenged on day 21 with WT virus.  Groups of 6 mice 
were infected with +2 or +4 virus.  Surviving animals were weighted thereafter.  All but 1 
+4 infected mouse succumbed by day 7 post challenge.  The number of surviving mice 
within these groups was recorded over the observation period.   
12 
 
 
 
Figure 3.  Regardless of initial infection, mice clear challenge virus from lungs by 
day 3.  Mice were infected on day 0 with virus (see legend) and then challenged on day 
21 with WT virus.  Some animals were sacrificed at regular intervals thereafter for lung 
titers. Lungs were collected, homogenized, and plated on MDCK cells to assess viral lung 
titers from each group containing 4 mice. 
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Chapter 4:  Protection in This Model Is Antibody Mediated 
 
 
 We questioned whether the protection or lack of protection seen in the sequential 
infections was antibody related.  To answer this question we used B-cell deficient mice to 
recapitulate the sequential infections.  If the protection is antibody mediated, then +2 
infected mice should now lose weight when challenged with WT in antibody deficient 
mice and +4 infected mice should show no changes.  Therefore, muMT mice were 
infected with WT, +2, or +4 and then challenged with WT on day 21.  Figure 4 shows 
that B-cell deficient mice are no longer protected from WT challenge and that there is a 
progressive pattern of disease dependent on glycosylation status.  Figure 5 shows the 
survival of these same mice, 75% of mice initially infected with +4 succumbed to WT 
challenge, whereas all WT and +2 initially infected mice survived WT challenge.  
Therefore, protection from WT challenge is at least partially dependent on antibodies, 
although the progressive disease pattern and the recovery of WT and +2 infected mice 
around day 3 suggest that T cells may also be important for protection. 
14 
 
  
 
Figure 4.  Protection conferred by +2 and WT viral infection against weight loss is 
antibody mediated.  B-cell deficient mice were infected as described in Figure 1.  
Groups of 4 mice were infected with +4, +2, or WT virus before challenge with WT 
virus.  Mice were then followed for weight loss. ANOVA analyses show a significant 
difference (P<0.05) between +4 and other groups on days 4-5.    
15
Figure 5.  Survival outcome in muMT animals.  The number of surviving mice within 
these groups was recorded over the observation period.  All but 1 +4 infected mice 
succumbed by day 7 post challenge. 
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Chapter 5:  Increasing Glycosylation Leads to a Decreased Antibody Response 
 
 
 We next looked at the specific antibody responses that were affected by 
glycosylation status.  We questioned whether glycosylation was affecting antibody 
quality or quantity, or whether it was a specific antibody deficit or a general one.  To do 
this, mice were infected with WT, +2, or +4 virus on day 0 and then bled for sera on day 
20.  This sera was then used in various immune assays to determine the antibody 
response to each of these viruses.  Figure 6a shows a Hemaglutination Inhibition Assay 
(HAI) with WT as a target.  Mice initially infected with +4 show less inhibition of WT 
HA than mice initially infected with WT or +2 (+2 data not shown).  Since HAI assays 
are not very specific and do not show the quality of antibody, we looked at 
microneutralization of influenza specific to WT.  Figure 6b shows that +4 infected mice 
show almost no neutralization of WT and that +4 infected mice show significantly less 
ability to neutralize WT than mice initially infected with WT or +2 (+2 data not shown).  
Next, we wanted to look at the amount of IgG generated by the glycosylation mutants.  
ELISAs were performed with an IgG antibody to detect the levels of IgG antibodies 
specific to WT.  Figure 6c shows that in +4 infected mice there is less IgG specific to 
WT; +2 infected mice show a titer between that of +4 infected mice and WT infected 
mice (+2 data not shown).  Since, microneutralization showed that these viruses differed 
in their ability to neutralize WT virus, we decided to also look at the amount of IgG2a 
generated, as this subtype is generally associated with non-neutralizing antibodies.  
ELISAs were again performed with an IgG1 and IgG2a antibody to determine its levels 
to the target virus.  As previously demonstrated, mice initially infected with +4 elicited 
less of a response against WT (data not shown).  These same immune assays were then 
run with +4 virus as the target.  Figure 6d shows hemagglutinin inhibition against +4 
virus is the same regardless of initial infection virus.  Figure 6e shows the same holds 
true for microneutralization.  Neutralization of +4 virus is very low regardless of 
infecting virus and is very low even in the case of homologous challenge.  Figure 6f 
shows the levels of IgG against +4 virus.  This also holds true for IgG1 and IgG2a (data 
not shown).  In each case WT infected mice show a higher titer than +4 infected mice.   
In general these data show, the more glycosylated a virus is the less of an antibody 
response it will induce.  This is most significant in the case of neutralizing antibodies as 
+4 has almost no ability to neutralize WT and even shows little ability to neutralize itself.  
Therefore glycosylation is reducing the overall quantity and quality of antibody response.  
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Figure 6.  +4 infected mice elicit lower antibody response than +2 and WT infected 
mice when assessed with WT as the target virus.  Mice were infected on day 0 with 
virus (see legend), bled for sera on day 20, and then assessed for various immune 
responses against WT.  (a)  Hemagglutinin Inhibition Assay (b) Microneutralization 
Assay (c) IgG ELISA.  Mice were also assessed for the same immune responses against 
+4.  (d) Hemagglutinin Inhibition Assay (e) Microneutralization Assay (f) IgG ELISA. 
ANOVA analyses (between groups comparisons) showed statistically significant 
differences between +4 responses and wt responses toward wt (p<.05) in assays for 
hemagglutination inhibition, microneutralization and ELISA titer. 
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 Chapter 6: T-Cell Responses after Virus Challenge 
 
 
T-Cell Response in This Model Can Be Both Harmful and Protective  
 
 After seeing that glycosylation status had a clear effect on antibody formation, we 
then questioned whether there was a similar effect on T cells.  We wanted to test the 
concept that T cells contributed to the antibody related protection seen in this model.   To 
determine if T cells were necessary for protection on WT challenge, mice were depleted 
of both CD4+ and CD8+ T cells.  Figure 7a shows that +2 infected mice were still 
protected from WT challenge.  Surprisingly, +4 infected mice when depleted of T cells 
on WT challenge were also protected, suggesting that the pathology may be T-cell 
mediated.  To determine if CD4+ or CD8+ T cells were responsible for this effect, +4 
infected mice were depleted of either CD4+ or CD8+ T cells on WT challenge.  Figure 
7b shows that this effect is mediated by both CD4+ and CD8+ T cells, seemingly equally.  
Therefore the pathology seen in mice first infected with a highly glycosylated virus and 
then challenged with WT is T-cell mediated.    
 
 
Highly Glycosylated Virus Leads to More Lung Pathology and Greater T-Cell 
Influx upon Challenge with WT 
 
 After seeing that mice initially infected with +4 caused more weight loss than 
initial infection with +2 or WT, we wanted to see the pathological effects on the lung as 
well as the T-cell influx in the lung of these same infections.  To examine the histological 
features associated with successive infection, mice were infected on day 0 with +4, +2, 
WT, or were mock-infected (PBS); mice were then challenged on day 21 with WT.  
Three days after challenge, lungs were harvested and stained for pathological 
examination.  Figure 8 a, b, c, and d show that the degree of pathology was directly 
associated with the level of glycosylation of the initial infection virus.  Lungs from mice 
infected with +4 show a greater degree of pathology than all other groups including 
mock-infected mice.  The pathology upon WT challenge decreased as the level of 
glycosylation of the initial infection decreases.  Lungs from the same mice were also 
stained for CD3, a marker.  Figure 9 a, b and c shows that the amount of T-cell infiltrate 
in the lung was directly related to the glycosylation status of initial infection.  Mice 
initially infected with +4 showed the greatest amount of CD3 staining followed by +2 
(data not shown), WT, and finally mock-infected.  These data show that in the case of 
successive infection, lung injury possibly due to greater T-cell response was exacerbated 
by the glycosylation status of the initial infection.  To further confirm this, mice were 
again infected and challenged as previously described.  On day 3 after challenge, 
broncho-alveolar lavage fluid (BAL) was collected and stained with anti-CD3 antibodies, 
anti-CD4 antibodies, and anti-CD8 antibodies.  FACS analysis was then performed to 
determine the relative number of total T cells, CD4+ T cells, and CD8+ T cells.   
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Figure 7.  Depletion of T cells upon WT challenge abolishes weight loss and death.  
Mice were infected as described previously.  (a)  +4 infected mice were depleted of both 
CD4+ and CD8+ T cells upon WT challenge at regular intervals and depletion was 
analyzed by FACS.  (b)  +4 infected mice were depleted of different subsets of T cells 
(see legend) upon WT challenge at regular intervals and depletion was analyzed by 
FACS.  ANOVA analyses showed a significant difference (P<0.05) between the 
undepleted group and all other groups on days 2-5. 
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Figure 8.  +4 infected mice show the greatest degree of lung damage 3 days post WT 
challenge.  Mice were infected on day 0 with +4, +2, WT, or PBS (mock-infected) and 
challenged on day 21 with WT.  3 Days post WT challenge lungs were harvested and 
stained for H+E to assess lung damage.  (a) +4 infected mice (b) +2 infected mice (c) 
WT infected mice (d) PBS (mock-infected) mice. 
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Figure 9.  +4 infected mice show the greatest amount of T-cell influx 3 days post WT 
challenge.  Mice were infected and lungs were harvested as in Figure 5.  Lungs were 
stained for CD3 to assess the influx of T cells.  (a) +4 infected mice (b) WT infected 
mice (c) PBS (mock-infected) mice. Arrows indicate high CD3 staining. 
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Figure 10a shows the total number of CD3+ cells for each group.  Mice infected with +4 
showed the highest amount of CD3+ T-cell influx in the lung, confirming previous 
findings.  Other groups show similar amounts of CD3+ T cells.  Figure 10b shows the 
amount of CD4+/CD8- T cell found in BAL fluid.  As described previously, +4 initially 
infected mice showed the highest number of CD4+/CD8- with the other groups having 
similar numbers of T cells.  Figure 10c shows the number of CD4-/CD8+ T cells found in 
the BAL of each group.  Mice infected with +4 again showed the highest number of 
CD4-/CD8+ T cells with a stepwise increase in this T-cell subset dependent on 
glycosylation status of the initial infection virus.  These data show that +4 infected mice 
have the greatest T-cell influx in the lung, as measured by three different T-cell subsets. 
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Figure 10.  +4 infected mice show the greatest amount of T-cell infiltrate in the 
lungs.  Mice were initially infected with +4, +2, WT, or PBS (mock infected) and 
challenged with WT on day 21 as previously described.  BAL fluid was collected from 
mice 3 day post WT challenge and stained with antibodies for CD3, CD4, and CD8 to 
assess the amount of T-cell infiltrate in the lungs.  Samples were analyzed by FACS.  (a) 
Number of CD3+ cells (b) Number of CD4+/CD8- cells (c) Number of CD4-/CD8+ 
cells. ANOVA analyses showed a significant difference (P<0.05) between +4 and other 
groups when CD3+ cells were compared. 
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Chapter 7:  Effect of Infection with a Heavily Glycosylated Virus on Delayed 
Challenge with a Virus Exhibiting Less Glycosylation 
 
 
Delayed WT Challenge Has No Effect on Pathology in +4 Infected Mice but 
Abolishes Protection Seen in +2 Infected Mice 
 
 To determine the long term consequences of successive infection, mice were 
infected with either +2 or +4 virus as previously described.  WT challenge was then 
delayed until day 121.  Mice were bled on day 120 to assess immune function.  Subsets 
of these mice were also depleted of CD4+ and CD8+ T cells on WT challenge as 
previously described.  Figure 11 shows that delayed WT challenge had no effect on the 
pathology associated with initial +4 infection.  Alternatively, +2 infected mice upon 
delayed WT challenge now showed pathology similar to that seen previously only in +4 
mice.  Also as described previously, T-cell depletion on WT challenge abolishes the 
pathology seen in this model.   
 
 
WT Virus Elicits an Improved Immune Response Compared to +4 Virus at the Day 
120 Time Point 
 
Figure 12a (hemagglutination inhibition), 12b (microneutralization), and 12c (IgG 
ELISA) show immune assays from sera collected at day 120.  As seen previously, +4 
initially infected mice generate lower responses on all immune assays, with +2 infected 
mice showing more (data not shown), and WT showing the greatest response.  
Interestingly, comparing day 120 immune responses (Figure 12) with day 20 immune 
responses (Figure 6) shows an overall increase in immune responses over time regardless 
of initial infecting virus.     
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Figure 11.  Delayed WT challenge has no effect on pathology seen in +4 infected 
mice but leads to a loss of protection in the case of +2 infected mice.  Mice were 
infected with +4 or +2 virus as described previously.  Mice were then bled on day 120 
and challenged with WT on day 121.  Sera from these mice were then used for immune 
assays.  Some mice were depleted of CD4+ and CD8+ T cells on WT challenge.  +4 and 
+2 infected mice (depleted and undepleted) were followed for weight loss after WT 
challenge.  
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Figure 12.  WT virus elicits an improved immune response compared to +4 virus at 
the day 120 time point.  Mice were infected with WT or +4 virus as previously 
described.  Mice were then bled on day 120 and challenged.  Sera from these mice were 
then tested in (a) Hemagglutination Inhibition Assay (b) Microneutralization Assay and 
(c) IgG ELISA 
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Chapter 8: Mice Suffer Pathology When Infected with a Seasonal H1N1 Isolate and 
Then Challenged with the S-OIV Swine Influenza, a Virus Exhibiting Less 
Glycosylation 
 
 
To look at the consequence of these successive infections in a model similar to 
that of the current S-OIV pandemic, mice were initially infected with Beijing/262/95 
(Bei) a seasonal isolate of H1N1 or with California/04/09 (Cali or S-OIV) a novel swine 
isolate.  Mice were then challenged with S-OIV and followed for weight loss.  Figure 13a 
shows that mice initially infected with the seasonal isolate lose weight upon S-OIV 
challenge while those initially infected with S-OIV did not.  Figure 13b and 13c show the 
lung pathology associated with these infections.  Mice initially infected with the seasonal 
isolate showed a greater degree of lung pathology upon S-OIV challenge.  Figure 14a and 
14b show CD3+ staining of these same mice.  Again, mice initially infected with the 
seasonal isolate showed a greater influx of CD3+ cells.    
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Figure 13.  Mice suffer pathology when infected with a seasonal H1N1 isolate and 
then challenged with S-OIV.  (a) Mice infected with a highly glycosylated H1N1 virus 
(Beijing/262/95) (Bei) can be re-infected with a non-glycosylated H1N1 virus 
(California/04/09) (Cali).  Mice were infected on day 0 with Bei or Cali and then were 
challenged with Cali on day 21. (b)  Lung histology (H+E) from mice infected with Bei 
then challenged with Cali (c) Lung histology (H+E) from mice infected with Cali then 
challenged with Cali (d) Lungs stained with CD3 after Bei/Cali infection (d) Lungs 
stained with CD3 after Cali/Cali infection. ANOVA analyses showed a significant 
difference (P<0.05) between Cali-infected and Bei-infected mice on day 2 and thereafter. 
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Chapter 9:  Impact of Results on Scientific Understanding and Future Goals 
 
  
Glycosylation and the Evolution of Influenza Virus 
 
 As each influenza subtype has evolved in the human population, they have 
gradually acquired more potential N-linked glycosylation sites around the globular head 
of the HA protein (see table 1).  On the other hand, the number of N-linked glycosylation 
sites in the stalk region of the HA have stayed relatively constant as they are involved in 
the folding and conformation of the protein.  This illustrates another common factor 
found in past human influenza pandemics, the lack of n-linked glycosylation on the 
globular head of HA.  Each of the virus subtypes (H1N1, H2N2, and H3N2) of past 
pandemics has acquired additional N-linked glycosylation sites as they have evolved in 
the human population (see table 1).   
   
 As previous studies in our lab have shown, one effect of increased glycosylation 
was decreasing virulence due to enhanced clearance by innate immune responses [9].  We 
proposed that this was the cost associated with evasion of the host adaptive immune 
response.  We used a series of viruses that differed only with respect to their 
glycosylation status to examine the effect of successive infections on the adaptive 
immune response.  We demonstrate here that highly glycosylated virus cannot protect 
against subsequent challenge with non-glycosylated virus.  This lack of protection is due 
to a lack of neutralization capability and also leads to T-cell-mediated pathology.  
Specifically, we believe that glycosylation is selectively blocking neutralizing antibody 
epitopes.  As we can see from these data, +4 infected mice have an IgG response towards 
WT despite being lower than other viruses.  The biggest differences were seen in the 
microneutralization assay, where +4 infected mice showed almost no ability to neutralize 
WT.  In fact, prior infection with a highly glycosylated virus leads to greater lung injury 
and T-cell pathology upon WT challenge than no prior infection at all.  These data 
indicate that glycosylation can inhibit cross-reactivity against an otherwise isogenic non-
glycosylated virus.  
  
 The idea that glycosylation of viral proteins could cause a defect in the formation 
of neutralizing antibodies against said protein is not new.  It has been shown in Simian 
Immunodeficiency Virus (SIV) that glycosylation of gp41 can shield epitopes that are 
targets for neutralization [12].  Removing these glycosylation sites leads to enhanced 
neutralization [12].  Further studies with SIV show similar enhanced neutralization with a 
deglycosylated gp120 mutant, although host factors also seem to play a role [13].  
Similarly, in Human Immunodeficiency Virus (HIV) removal of one N-linked glycan 
from gp120 results in enhanced ability to induce neutralizing antibodies [14].  It has been 
widely shown in the HIV field that neutralizing antibodies play an important role in 
protection against HIV and that the generation of these neutralizing antibodies is difficult, 
possibly due to glycosylation (reviewed in [15]).  For many viruses, including influenza, 
the generation of neutralizing antibodies is a key part of vaccine development [14-16].  
The clear deficit in neutralization seen in these studies leads us to conclude that the main 
role of glycosylation on the globular head of influenza HA is to block the formation of 
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neutralizing antibodies.  Recent research has shown that neutralizing antibodies against 
H3N2 viruses can be divided into three main groups. These groups are divided by year 
with 1968-1973, 1977-1993, and 1997-2003 being the years that the antibodies could 
effectively neutralize.  In other words, antibodies that neutralize one group were not 
efficient in neutralizing virus outside of that range of years [17]. These ranges of years 
correlate quite well with the addition of glycosylation sites (table 1).  1973 marks the 
addition of a site as well as the end of one neutralization group, 1977 marks the inclusion 
of a second site, and 1997 marks the addition of a third site.  It is interesting to note, 
especially in light of the data shown here, that the addition of glycosylation seems to 
strongly correlate with the need for different neutralizing antibodies.  By evading 
neutralization, the virus can still set up an infection allowing for some replication and 
viral transmission.  This can be seen in the case of mice initially infected with +4 virus 
which show signs of virus in the lungs on day 1 (Figure 3) despite any signs of non T-
cell-mediated pathology.  In other words, there is virus present in the host as a subclinical 
infection that still allows viral transmission.  This is the ideal situation for any virus, 
allowing the virus to multiply and spread without harming the host.  The studies in this 
paper and those performed previously in this lab suggest this is the one possible 
consequence of glycosylation in the context of influenza, as glycosylated viruses have 
been shown to be less virulent and to elicit less of an antibody response.    
  
 
Influenza Virus Glycosylation and Disease 
 
 Recently the human population has faced the threat of another influenza 
pandemic, the H1N1 swine-origin virus (S-OIV).  Despite the fact that flu season had just 
started, there were 8651 confirmed deaths as of November 25, 2009 along with millions 
of potential cases.  Unlike seasonal influenza, which affects mostly the young and the 
old, a significant portion of these cases occurred in the middle age group.  During one 
period studied, 87% of deaths and 71% of cases of severe pneumonia, a common 
complication of influenza, occurred in patients aged between 5 and 59.  This is in contrast 
to the average rates of 17% of deaths and 32% of cases of severe pneumonia associated 
with seasonal influenza in this age group [18].  In another study, over half of the case 
patients were between 13 and 47 years of age [19].  Both of these studies were 
characterized by severe respiratory disease [18;19].  Studies have also shown that there is 
very little pre-existing immunity towards S-OIV.  Specifically, only 1/6 B-cell epitopes in 
the HA and NA are conserved while T-cell epitopes are much more conserved, 54/78 of 
CD8+ T-cell epitopes [12].  It should be noted that similar to previous human pandemics, 
the H1N1 swine flu has no glycosylation on the globular head of it’s HA protein, while 
recent seasonal isolates have these glycosylation sites.  The data shown here in the 
context of an H3N2 virus could have some bearing on the current pandemic.  As stated 
previously, S-OIV has been unusually severe in the middle age group when compared to 
seasonal isolates.  It is possible that some of this is due to T-cell pathology due to 
glycosylation status as seen in these studies.  Only relatively healthy mice showed this T-
cell pathology, as in B-cell deficient mice T cells aid in recovery.  It is possible that this 
is what we are seeing in the middle age group that is generally considered to be not as 
susceptible to influenza infection.  This is not normally an issue as the glycosylation 
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status of influenza virus has been increasing and this is seemingly the first time a virus 
has gone backwards.  As each new influenza subtype has emerged in the human 
population, generally as a pandemic virus, they have all lacked glycosylation on the 
globular head of the HA protein.  As each of these subtypes has evolved in the human 
population, they have each added glycosylation sites.  It seems clear at this point that the 
addition of N-linked glycosylation sites to the globular head of the influenza HA protein 
gives the virus some evolutionary advantage.  We propose one such advantage here, 
namely the setup of a situation that allows for a subclinical infection and viral 
transmission.  We believe that this occurs through the blockage of neutralization and 
neutralizing antibodies by glycosylation. 
 
 In the influenza field, much work has been done to optimize the seasonal 
influenza vaccine.  There are many factors that make this particular goal difficult to 
achieve.  One such factor is that of original antigenic sin (OAS)[20-23].  OAS refers to 
the preferential generation of antibodies against the first antigen seen by the immune 
system.  After a primary infection with one influenza isolate, subsequent infection with a 
different isolate can lead to the immune response still being directed against the original 
isolate [24].  Another such factor is the occasional difficulty in generating neutralizing 
antibodies, which have been shown to be important for subsequent protection [16].  It has 
been shown previously that glycosylation can shield influenza from neutralizing 
antibodies [25].  We have seen similar findings in the data shown here.  The 
glycosylation status of the vaccine strain could have some effect on the ability of said 
vaccine to elicit an effective antibody response.  Also if we see reversal of glycosylation 
status again, as we have seen with S-OIV, vaccination with a glycosylated virus could 
actually be more harmful than protective.  It is also possible that glycosylation plays 
some role in the lack of cross protection seen in the case of S-OIV and in the case of 
H5N1, as both of these viruses lack glycosylation on the globular head.  Therefore we 
believe that more research needs to be done on the potential of non-glycosylated 
vaccines, as they may be more beneficial in protecting the population from future 
influenza isolates.  These findings could have a major impact in vaccine design and be 
particularly relevant in the context of the current S-OIV pandemic.   
  
 
Future Directions 
 
 To investigate if the T-cell pathology seen in these studies is dependent on the 
discussed antibody mismatch and lack of neutralization some extra studies are necessary.  
To address this concern we will carry out passive antibody transfer studies in B-cell 
deficient mice [26].   muMT mice lacking B-cells will be infected with +4 virus and 
challenged with WT virus as previously described.  One group of these mice will then be 
given sera from fully competent mice that were previously infected with +4, while the 
other group will be given no sera.  As discussed previously, muMT mice infected with +4 
virus, then challenged with WT lose weight and eventually succumb to WT challenge, 
while continuing to have detectable virus in the lungs, whereas immune competent mice 
succumb to challenge with no detectable virus found in the lungs on day three.  We 
expect to see these same results in the muMT group receiving +4 sera, specifically these 
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mice will still succumb to challenge despite lack of detectable virus in the lungs.  Lungs 
from each group of muMT mice can also be stained for CD3+ to determine if the group 
receiving +4 sera has a greater influx of T cells on WT challenge.  Based on previous 
studies, we expect this will be the case.  These studies will help clarify the nature of the 
observed T-cell pathology in relation to the previously seen lack of neutralization and 
will help clarify the mechanism of T-cell pathology. 
 
 While we have hypothesized that these studies carried out in H3N2 viruses can 
translate to H1N1 viruses specifically the current swine flu epidemic.  While we have 
shown some data that leads us to believe that these studies are relevant in the context of 
H1N1 viruses, further research is necessary to support these conclusions.  These same 
experiments can be recapitulated on an H1N1 virus.  To do this, glycosylation sites will 
be added to the H1N1 swine flu, which as discussed previously lacks glycosylation on the 
globular head of its HA.  These created viruses can then be used in the same successive 
infection studies as performed previously.  If glycosylation in an H1N1 virus has a 
similar effect on host immune reaction, we would expect to see similar results to the one 
seen here.  This work is currently underway in our laboratory. 
 
 As the search for more effective vaccination against influenza continues, another 
significant question to ask is the impact of glycosylation on vaccine efficacy.  As we have 
seen in an H3N2 virus, the more glycosylation sites a virus has the less of an antibody 
response it generates in general and specifically towards a lesser glycosylated virus; but 
what impact will this have in the real world where viruses mutate rapidly?  Will 
glycosylated viruses be more effective against future strains which tend to add 
glycosylation sites as they evolve or will the increased antibodies generated against 
relatively non-glycosylated viruses be more valuable?  What will happen in the future if 
we see a reversal of glycosylation similar to that seen in the current swine flu epidemic?  
Many different studies could be done on this subject.  To start to address these questions 
a series of vaccines could be created containing differing glycosylation.  These vaccines 
could then be used to inoculate mice prior to challenge with different viruses, also 
containing differing glycosylation.  These mice will then be accessed for morbidity, 
mortality, and antibody response.  These studies will allow us to determine the 
glycosylation status that is most effective against a range of challenge viruses. 
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